119 related articles for article (PubMed ID: 38401351)
21. Evaluation of tumor regression by neoadjuvant chemotherapy regimens for esophageal adenocarcinoma: a systematic review and meta-analysis.
Chidambaram S; Sounderajah V; Maynard N; Owen R; Markar SR
Dis Esophagus; 2023 Jan; 36(2):. PubMed ID: 36151055
[TBL] [Abstract][Full Text] [Related]
22. Impact of response evaluation for resectable esophageal adenocarcinoma - a retrospective cohort study.
Bachmann R; Bachmann J; Hungbauer A; Schmehl J; Sitzmann G; Königsrainer A; Ladurner R
Int J Surg; 2014 Oct; 12(10):1025-30. PubMed ID: 25192805
[TBL] [Abstract][Full Text] [Related]
23. Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study.
Bollschweiler E; Hölscher AH; Herbold T; Metzger R; Alakus H; Schmidt H; Drebber U; Warnecke-Eberz U
Ann Surg; 2016 Nov; 264(5):839-846. PubMed ID: 27741011
[TBL] [Abstract][Full Text] [Related]
24. The Impact of Tumor Regression on Prognosis After Neoadjuvant Chemoradiotherapy in Surgically Treated Esophageal Adenocarcinoma.
Crull DJ; Hogenes MCH; Hoekstra R; Hendriksen EM; van Det MJ; Kouwenhoven EA
Ann Surg Oncol; 2022 Jun; 29(6):3658-3666. PubMed ID: 35094189
[TBL] [Abstract][Full Text] [Related]
25. Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
Tang H; Jiang D; Zhang S; Zeng Z; Tan L; Hou Y; Wang Q; ; Wang H; Zhu J; Shen Y; Yin J; Ge D
J Thorac Cardiovasc Surg; 2021 Dec; 162(6):1632-1641. PubMed ID: 33268125
[TBL] [Abstract][Full Text] [Related]
26. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
[TBL] [Abstract][Full Text] [Related]
27. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).
Hoeppner J; Lordick F; Brunner T; Glatz T; Bronsert P; Röthling N; Schmoor C; Lorenz D; Ell C; Hopt UT; Siewert JR
BMC Cancer; 2016 Jul; 16():503. PubMed ID: 27435280
[TBL] [Abstract][Full Text] [Related]
28. Addition of HER2 and CD44 to
Beukinga RJ; Wang D; Karrenbeld A; Dijksterhuis WPM; Faber H; Burgerhof JGM; Mul VEM; Slart RHJA; Coppes RP; Plukker JTM
Eur Radiol; 2021 May; 31(5):3306-3314. PubMed ID: 33151397
[TBL] [Abstract][Full Text] [Related]
29. Pathologic Complete Response Is an Independent Predictor of Improved Survival Following Neoadjuvant Chemoradiation for Esophageal Adenocarcinoma.
Alnaji RM; Du W; Gabriel E; Singla S; Attwood K; Nava H; Malhotra U; Hochwald SN; Kukar M
J Gastrointest Surg; 2016 Sep; 20(9):1541-6. PubMed ID: 27260525
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma.
Groth SS; Burt BM; Farjah F; Smaglo BG; Sada YH; Sugarbaker DJ; Massarweh NN
J Thorac Cardiovasc Surg; 2019 Apr; 157(4):1682-1693.e1. PubMed ID: 30711279
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.
Metzger R; Warnecke-Eberz U; Alakus H; Kütting F; Brabender J; Vallböhmer D; Grimminger PP; Mönig SP; Drebber U; Hölscher AH; Bollschweiler E
J Gastrointest Surg; 2012 Jan; 16(1):26-34; discussion 34. PubMed ID: 21956434
[TBL] [Abstract][Full Text] [Related]
32. The value of tumor-stroma ratio as predictor of pathologic response after neoadjuvant chemoradiotherapy in esophageal cancer.
van Pelt GW; Krol JA; Lips IM; Peters FP; van Klaveren D; Boonstra JJ; de Steur WO; Tollenaar RAEM; Farina Sarasqueta A; Mesker WE; Slingerland M
Clin Transl Radiat Oncol; 2020 Jan; 20():39-44. PubMed ID: 31886418
[TBL] [Abstract][Full Text] [Related]
33. The benefit of PET/CT in the diagnosis and treatment of esophageal cancer.
Vomackova K; Neoral C; Aujeský R; Vrba R; Stasek M; Myslivecek M; Formánek R
Rozhl Chir; 2015 Jan; 94(1):8-16. PubMed ID: 25604979
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
35. Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.
Schwameis K; Zehetner J; Hagen JA; Oh DS; Worrell SG; Rona K; Cheng N; Samaan J; Green KM; Lipham JC
Surg Oncol; 2017 Dec; 26(4):522-526. PubMed ID: 29113673
[TBL] [Abstract][Full Text] [Related]
36. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results.
Mamede M; Abreu-E-Lima P; Oliva MR; Nosé V; Mamon H; Gerbaudo VH
Am J Clin Oncol; 2007 Aug; 30(4):377-88. PubMed ID: 17762438
[TBL] [Abstract][Full Text] [Related]
37. 18F FDG-PET/CT evaluation of histological response after neoadjuvant treatment in patients with cancer of the esophagus or gastroesophageal junction.
Gabrielson S; Sanchez-Crespo A; Klevebro F; Axelsson R; Albert Tsai J; Johansson O; Nilsson M
Acta Radiol; 2019 May; 60(5):578-585. PubMed ID: 30111193
[TBL] [Abstract][Full Text] [Related]
38. Volumetric parameters of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography/computed tomography can predict histopathologic treatment response after neoadjuvant chemoradiotherapy in pancreatic adenocarcinoma.
Sakane M; Tatsumi M; Hori M; Onishi H; Tsuboyama T; Nakamoto A; Ota T; Eguchi H; Wakasa K; Hatazawa J; Tomiyama N
Eur J Radiol; 2017 Sep; 94():64-69. PubMed ID: 28712692
[TBL] [Abstract][Full Text] [Related]
39. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
40. Tumor volume reduction assessed by planning computed tomography in patients with rectal cancer during preoperative chemoradiation: impact of residual tumor volume on the prediction of pathologic tumor regression.
Lee JA; Yang D; Yoon WS; Park YJ; Kim CY; Moon HY; Lee SI
Tumori; 2014; 100(2):158-62. PubMed ID: 24852859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
